Cancer Vaccine Adjuvant Name Recognition from Biomedical Literature using Large Language Models
Hasin Rehana, Jie Zheng, Leo Yeh, Benu Bansal, Nur Bengisu Çam, Christianah Jemiyo, Brett McGregor, Arzucan Özgür, Yongqun He, Junguk Hur
Code Available — Be the first to reproduce this paper.
ReproduceCode
- github.com/hurlab/vaccine-adjuvant-llmOfficialIn papernone★ 1
Abstract
Motivation: An adjuvant is a chemical incorporated into vaccines that enhances their efficacy by improving the immune response. Identifying adjuvant names from cancer vaccine studies is essential for furthering research and enhancing immunotherapies. However, the manual curation from the constantly expanding biomedical literature poses significant challenges. This study explores the automated recognition of vaccine adjuvant names using Large Language Models (LLMs), specifically Generative Pretrained Transformers (GPT) and Large Language Model Meta AI (Llama). Methods: We utilized two datasets: 97 clinical trial records from AdjuvareDB and 290 abstracts annotated with the Vaccine Adjuvant Compendium (VAC). GPT-4o and Llama 3.2 were employed in zero-shot and few-shot learning paradigms with up to four examples per prompt. Prompts explicitly targeted adjuvant names, testing the impact of contextual information such as substances or interventions. Outputs underwent automated and manual validation for accuracy and consistency. Results: GPT-4o attained 100% Precision across all situations while exhibiting notable improve in Recall and F1-scores, particularly with incorporating interventions. On the VAC dataset, GPT-4o achieved a maximum F1-score of 77.32% with interventions, surpassing Llama-3.2-3B by approximately 2%. On the AdjuvareDB dataset, GPT-4o reached an F1-score of 81.67% for three-shot prompting with interventions, surpassing Llama-3.2-3 B's maximum F1-score of 65.62%. Conclusion: Our findings demonstrate that LLMs excel at identifying adjuvant names, including rare variations of naming representation. This study emphasizes the capability of LLMs to enhance cancer vaccine development by efficiently extracting insights. Future work aims to broaden the framework to encompass various biomedical literature and enhance model generalizability across various vaccines and adjuvants.